Jump to content

Myths & Legends! The Santa Rally & More...


Recommended Posts

Hi Fellow Traders,

 

I’m sure we’ve all heard of them, the Monday Effect, the Santa rally to name just a couple. The trading perceptions that supposedly happen repeatedly every year, week or with an event such as Christmas or Holiday seasons.

 

I personally have found the Santa Rally to have some basis to it.  Even just simply buying the FTSE100 on the 1st of December and selling before the New Year should overall show a positive expectation. I believe the Monday Effect to also be marginally true, but the difference is so slim that it can’t be traded without any other indicators.

 

My question to you all is what trades like this do you have that happen over and over again? It could be something that you know to be true and rely upon, or It could be theories that you believe to be utter rubbish. The more ridiculous the better! As long as it’s tradeable on IG I’d love to hear them?

Link to comment

Would it not be more effective to look at FTSE in the last 20 years and see how much money you would have made/lost from your Santa trade?

 

I once won a "stock investing" competition by simply buying all of the one-letter American Stock.  A, B, C, etc.

Link to comment
  • 2 years later...

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • General Statistics

    • Total Topics
      15,674
    • Total Posts
      74,994
    • Total Members
      63,042
    • Most Online
      7,522
      10/06/21 10:53

    Newest Member
    SelfIsolating2021
    Joined 27/07/21 09:14
  • Posts

    • Gold falls back into support as Brent crude pushes into Fibonacci resistance Gold falls back into key support, while Brent crude has rallied up into Fibonacci resistance in its bid to regain previous highs. Source: Bloomberg    Joshua Mahony | Senior Market Analyst, London | Publication date: Tuesday 27 July 2021  Gold drifts back into key support level Gold has been on the back foot once again, with price moving back into the key $1790 support level. A break below that level would bring a bearish picture into play following a period of consolidation. However, with price typically managing to post a short rebound from this level, it is worthwhile expecting another move higher until we see $1790 break. Source: ProRealTime   Brent crude rallies back into Fibonacci resistance Brent crude has been on the rise since a pullback into the wider 76.4% Fibonacci retracement level at $67.60. That rally has brought us back into yet another 76.4% level at $74.12. The wider uptrend points towards a likely push up through this level in a bid to regain the previous peaks of $76.30 and $77.57. However, whether that will come in a straight line remains to be seen. For now, we need to see whether price respects that Fibonacci resistance level or simply pushes through. To the downside, any pullback would need to break the $72.14 level to bring a more bearish short-term outlook. Until then, there is a good chance we see further upside come into play. Source: ProRealTime   See opportunity on a commodity?  
    • Astrazeneca Q2 revenue is expected to show strong growth, although an increased cost base will pressure underlying earnings. Source: Bloomberg   Shares AstraZeneca Price Revenue Earnings before interest, taxes, depreciation and amortization Technical analysis  Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Tuesday 27 July 2021  When are the AstraZeneca results? AstraZeneca, the biopharmaceutical company, earnings release date is scheduled for 27 July 2021. The scheduled results will cover the groups second quarter (Q2) and half-year earnings. What to expect from AstraZeneca results? While a large Covid-19 vaccine rollout will have boosted revenue for the group, it would have done little for underlying earnings due to the company selling the product as a non-profit item. Consensus estimates derived from Refinitiv data arrives at the following expectations for Q2 of 2021: Revenue $7.530 billion (+20%) year on year (YoY) Earnings before interest tax depreciation amortisation (EBITDA) $2.233 billion (-10.75% YoY) Earnings per share (EPS) $0.93 (-3.01% YoY) What is expected to be accretive to future earnings for the group (although may weigh in the short term) is the groups acquisition of biopharmaceutical business Alexion, which was concluded on 21 July 2021, shortly after the reporting quarter. Find out more on how to buy, sell and short AstraZeneca shares How to trade AstraZeneca results A Refinitiv poll of 29 analysts maintain a long-term average rating of ‘buy’ for AstraZeneca (as of 26 July 2021), with 10 of these analysts recommending a strong buy, 16 recommending a buy, 1 hold, 1 sell and 1 strong sell recommendation on the stock. Source: IG AstraZeneca share price – technical analysis view Source: IG charts   The share price of AstraZeneca continues to trade in an uptrend which has been in place since the beginning of 2021. The price has however started to correct from near-term highs. Traders respecting the longer-term uptrend will prefer to keep a long bias to trades targeting a retest of the 8770 level, provided that the price does not move to break the confluence of both trend line and horizontal support at the 7800 level. A break of the 7800 level would instead suggest the uptrend to be broken. In summary AstraZeneca results are scheduled for release on 27 July 2021 Q2 revenue of $7.530 billion is expected Q2 EBITDA of $2.223 billion is expected EPS of $0.93 is expected The average broker rating for AstraZeneca is ‘buy’ The share price of AstraZeneca is currently in a short term correction of a longer-term uptrend
×
×
  • Create New...